These studies include the NEOTOMA trial, which is evaluating tremelimumab and durvalumab in resectable HCC, and a different trial of a LAG3 inhibitor in addition to nivolumab among patients with potentially resectable HCC. This evidence concerns the gene LAG3 and hepatocellular carcinoma.